UCX® have the potential to promote a full range of events leading to tissue regeneration and homeostasis as demonstrated in induced hindlimb ischemia (HLI) in animal models. UCX® was shown to enhance angiogenesis in vitro via a paracrine effect. Importantly, [...]
Self-assembled 3D spheroids and hollow-fibre bioreactors improve UCX®-derived hepatocyte-like cell maturation in vitro
3D cultures of human stem cell-derived hepatocyte-like cells (HLCs) have emerged as promising models for short- and long-term maintenance of hepatocyte phenotype in vitro cultures by better resembling the in vivo environment of the liver and consequently increase the translational [...]
ECBio’s SI I&DT grant for the clinical development of UCX® in the area of Peripheral Artery Disease (PAD) – involving a Phase I/IIa clinical trial, has been approved by the PT2020 programme. Congratulations ECBio.
ECBio’s Patent on the Optimised and Defined Method For Isolation And Preservation Of Precursor Cells From Human Umbilical Cord has been granted in Europe.
ECBio's European patent application Nº 08807881, and Pub.Nº EP2203555, on the OPTIMISED AND DEFINED METHOD FOR ISOLATION AND PRESERVATION OF PRECURSOR CELLS FROM HUMAN UMBILICAL CORD has been granted in Europe. Congratulations ECBio.
The ClinUCX R&D project reveals extraordinary advancements on the effects of UCX® application in a PAD model
ECBio´s work in straight collaboration with AIDFM/FMUL, shows for the first time that UCX® can stimulate angiogenesis and arteriogenesis, and thereby improve blood perfusion in the ischemic limbin of experimentally induced hind limb ischemia in vivo. These results suggest that [...]
A long term evaluation of the UCX® cardioprotective effect after MI induction in vivo has revealed an even more drastic functional improvemnt of the performance of the ischemic myocardium when compared to the controls. A robust microultrasound system, with higher [...]
ECBio´s latest research on UCX® potency and mechanism of action has revealed relevant differences between MSCs from different origins. To elucidate the potency differences observed between UCX® and BM-MSCs, gene expression related to immune modulation was analysed in both cell [...]
ECBio will be at the ISSCR annual meeting"An Unveiling of Stem Cell Innovation", Stockholm 24-27 June. Meet us at the posters sessions and discuss UCX® immunomodulatory and agiogenic potency and how it may, or may not, be affected by cryopreservation. [...]
ECBio and its collaborators at FFUL and INEB have shown how to improve the therapeutic potency of UCX
Congratulations ECBio. Stem Cell Research & Therapy.2015, 6:90 DOI: 10.1186/s13287-015-0082-5